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You may be aware of some recent media comments regarding the current ICGP best practice 
guidelines “Working with Opiate Users in Community Based Primary Care ”.  There were a number of 
concerns raised which were addressed when the Best Practice Guidelines Committee was recalled to 
discuss the matters raised.  
 
We wish to advise you that the ICGP is confident that these Guidelines are evidenced based where 
possible and are supported by the experience of experts in the field where evidence is not available. 
We also wish to remind all practitioners that best practice guidelines provide guidance on what is 
considered best practice; they are not a substitute for clinical judgement.  
In view of the concerns raised we wish to add the following addendums to the existing guidelines: 
 
 Page 17 of the guidelines in relation to incrementing doses: in addition to the statement 
“Increments should be no greater than 10mg at a time” we wish to add that the “total dose 
increases should not exceed 20-30mg in one week”.  
 
 Page 17 of the guidelines under section 2, Commencing and Stabilising on Methadone 
Treatment the statement “Patients usually stabilise on doses between 60mg to 80mg” 
should read “Patients usually stabilise on doses between 60mg to 120mg”. This is in line 
with international best practice guidelines. However we recommend that this statement is 
read in the context of the complete section on commencing doses 
 
 Pg 17 of the guidelines: It is not intended to suggest that > 80mg would be interpreted as a 
high dose. In the interest of clarity, this statement could be read  “Higher doses of 
methadone...”  rather than “Higher doses of methadone ( >80mgs)....”. Similarly, in the 
section under Remember on page 18, this sentence should read “if a patient requires a 
higher dose and you have limited experience...” rather than “if a patient requires a dose 
>80mgs and you have limited experience...” 
 
The current guidelines are now available only through the ICGP website (we are not doing a further 
print run as the guidelines are currently under review). Please note the addendums above will be 
added to the on-line version of the Guidelines. Dr Cathal O Sullivan has asked that his name be 
removed from the Guidelines because of the concerns he raised and this has also been done on the 
on-line version. 
 
Following the publication of the Opiate Treatment Review in December 2010, new National 
Guidelines are currently being developed in conjunction with the Irish College of Psychiatrists, the 
ICGP, the HSE and the Pharmaceutical Society of Ireland. The first draft of these Guidelines will be 
available for review early 2012 and will be circulated to all stakeholders for comment before 
publication. The nominated ICGP representatives on the MTP National Guidelines group are Dr. Des 
Crowley and Dr Harkin. 
If you have queries with regard to the addendums, please to not hesitate to contact a member of 





Introduction                                                                                                                               4
Chapter 1 – The Methadone Treatment Protocol                                                                   5
1 GP Training in Drug Misuse                                                                                            5
1.1 Level One Training                                                                                             5
1.2 Level Two Training                                                                                            5
1.3 Continuing Medical Education                                                                          5
1.4 Annual Audit                                                                                                       6
2 Models of Care for Drug Misusers                                                                                  6
2.1 Level 2 GP Services                                                                                            6
2.2 Level 1 GP Services                                                                                            6
2.3 Treatment Centres                                                                                               6
2.4 Satelitte Clinics                                                                                                   7
2.5 Inpatient Detoxification                                                                                      7
2.6 Rehabilitation Programmes                                                                                7
3 Research and Development                                                                                              7
Chapter 2 – Aims & Objectives of Treatment                                                                         8
Chapter 3 – Assessment and Management Options                                                               9
1 Initial Assessment                                                                                                             9
1.1 Explore Realistic Goals                                                                                      9
1.2 Discuss Practice Policies                                                                                    9
1.3 Take Drug History                                                                                              10
1.4 Assess the presence                                                                                             10
1.5 Explore Patients Expectations                                                                            11
2 Urine Screening                                                                                                                 11
3 Management Options                                                                                                        12
3.1 General Management Principles                                                                        12
Chapter 4 – Detoxification                                                                                                          14
1 Self Detox                                                                                                                          14
2 Symptomatic Detox                                                                                                          14
Chapter 5 – Methadone Treatment                                                                                           16
1 Evidence base for Methadone Treatment                                                                        16
2 Commencing and Stabilising on Methadone Treatment                                                17
3 Dispensing Instructions for Methadone                                                                          18
4 Detoxification and Methadone Reductions Regimes                                                     20
4.1 Detoxification                                                                                                      20
4.2 Slow Reduction of Methadone                                                                           21
5 Monitoring and Review                                                                                                    22
6 Destabilisation                                                                                                                   23
6.1 Managing a patient who has destabilised                                                          24
Chapter 6 – Special Groups and Substitute Prescribing                                                       26
1 Adolescents                                                                                                                       26
1.1 Parental Consent                                                                                                 26
1.2 Treatment                                                                                                             26
2 Pregnancy in Opiate Dependent Women                                                                        27
2.1 Breast-feeding                                                                                                     28
2.2 Neonatal Abstinence Syndrome                                                                         28
3 Pyschiatric Co-morbidity or Dual Diagnosis                                                                  28
3.1 Depression                                                                                                           28
3.2 Anxiety/Paranoia                                                                                                 29
3
Chapter 7 – Drug Related Deaths and Overdose                                                                    30
Chapter 8 – Problem Section                                                                                                      32
1 Missing the Chemist                                                                                                         32
2 False Urines                                                                                                                       33
3 Special Dispensing Arrangements                                                                                   33
3.1 Public Holidays and Bank Holidays                                                                          33
3.2 Holidays                                                                                                                       33
3.3 Prison                                                                                                                           34
3.4 Hospital                                                                                                                       34
4 Needle-Stick Injuries                                                                                                        35
4.1 Hepatitis B                                                                                                                   35
4.2 Hepatitis C                                                                                                                   35
4.3 HIV                                                                                                                              35
5 Drug Driving                                                                                                                     36
Chapter 9 – Management of other Drugs of Misuse                                                               37
1 Alcohol                                                                                                                               38
2 Benzodiazepines                                                                                                               38
3 Cannabis                                                                                                                            39
4 Ecstasy                                                                                                                               40
5 Cocaine                                                                                                                              40
6 Amphetamines                                                                                                                   41
Chapter 10 – Blood Borne Viruses in Opiate Users                                                                42
1 Hepatitis C                                                                                                                         42
2 Human Immunodeficiency Virus                                                                                    44
2.1 Immunopathogenesis                                                                                                  44
2.2 Milestones in the history of HIV                                                                               44
2.3 Natural history of HIV                                                                                               44
2.4 Initial HIV Infection                                                                                                   45
2.5 Routes of HIV transmission                                                                                       45
2.6 Treatment of HIV                                                                                                       46
2.7 When is HAART initiated                                                                                          46
2.8 Psychological aspects of HIV disease                                                                       47
2.9 Prevalence                                                                                                                   47
2.10 HIV positive testing                                                                                                 47
2.11 HIV testing                                                                                                                48
3 Hepatitis B                                                                                                                         49
3.1 Hepatitis B serological markers                                                                                 49
4 Vaccination Schedules                                                                                                      51
Chapter 11 – Non-Methadone Alternative Therapies                                                            52
1 Buprenorphine (Subutex) and Buprenorphine/Naloxone (Suboxone)                          52
2 Lofexidine                                                                                                                          52
Appendix A – Audit Criteria                                                                                                          53
Appendix B – HSE Treatment Centres and Local Co-ordinators                                               54
Appendix C – Sample Agreement                                                                                                 56
Appendix D – Addiction Assessment                                                                                           57
Appendix E – Excretion Times                                                                                                      62
Appendix F – Methadone Prescription Forms                                                                              63
Appendix G – Glossary of Terms                                                                                                  66
Appendix H – Conversion Table                                                                                                   67
Appendix I –  Recommended Reading List                                                                                  68
Appendix J –  Useful Websites                                                                                                      69
4
Introduction
It is well recognised that GPs have a pivotal role to play in the management of drug
users and many GPs who manage drug users in practice have found this work to be a
rewarding professional experience. As addiction is a chronic relapsing condition, the
GP’s unique knowledge of the patient and their extended family can make a
considerable contribution to the long-term management of drug using patients.
Drug treatment services have expanded significantly throughout Ireland since the
publication of Report of the Methadone Treatment Services Review Group5 in 1998.
This report recommended a change in the way methadone could be prescribed and
dispensed in Ireland and the existing Misuse of Drugs Act was amended to reflect
these recommendations. It further recommended that all GPs involved in providing
methadone treatment should receive suitable training. It also outlined a variety of
models of care which now operate in the primary care setting and in HSE based
clinics. The format for how Methadone is regulated and how opiate dependant
patients are managed is now commonly known as the Methadone Treatment Protocol
(MTP).
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Chapter 1 The Methadone Treatment Protocol
1 GP Training in Drug Misuse
With the spread of problem drug use nationally, GP’s will increasingly be confronted
with the health consequences of problem drug users. It is important for clinicians to
ensure that they are competent to treat drug misusers.  Doctors completing their
training in general practice should have received Level 1 training before graduating
from their training programme. Regular Level 1 training courses are provided by the
ICGP throughout the year (details available on the ICGP website)6.
1.1 Level One Training
Level 1 training is provided in two modules over two separate evening meetings. This
course provides the foundation for treating stable methadone maintained patients in
general practice.  Having completed this training a GP may accept up to fifteen
patients for methadone maintenance treatment. Stabilisation usually takes place in a
health board treatment centre but may also be offered by a suitably trained GP
colleague (Level 2). Referral between Level 1 and Level 2 GPs is encouraged where
this option is available.
1.2 Level Two Training
A GP is eligible to apply for Level 2 training once the following criteria have been
fulfilled:
• the GP should have managed at least five patients on the MTP for a minimum
of one year.
• the GP should have successfully completed an external clinical audit
conducted by the ICGP
Following the required training which currently requires 13 clinical sessions
supervised by a GP mentor, a Level 2 GP may initiate treatment, stabilise a drug user
and provide ongoing maintenance treatment in the primary care setting. A successful
external Level 2 audit completes the accreditation process.
Further information on the Level1 and Level 2 training and accreditation criteria can
be obtained from the ICGP website.6
1.3 Continuing Medical Education
After completing Level 2 training, the GP is expected at engage in regular continuing
medical education.  In these sessions a wide range of issues relating to community
based drug treatment are addressed.
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1.4 Annual Audit
Regular audit is provided by an ICGP/HSE appointed audit nurse. The format for the
audit is regularly updated and revised as appropriate. The range of care provided by
the GP to his/her methadone patients is reviewed and referenced to the current best
practice guidelines issued by the ICGP. See Appendix A.
2 Models of Care for Drug Misusers
There are a range of models of service delivery to drug users throughout the country.
Within the greater Dublin area all models of care co-exist. Outside of the Eastern
region, services are more limited and are generally confined to Satellite clinics and
Level 1 and Level 2 GPs. Ideally all treatment services should have multidisciplinary
care teams which include doctors, nurses, addiction counsellors and access to
community welfare officers and social workers.
2.1 Level 2 GP Services
Level 2 GPs are trained to do an initial assessment and to initiate methadone
treatment. Once a patient has been stabilised on the programme the Level 2 GP can
provide ongoing care and methadone maintenance.
In some areas a system of inter-GP referral can operate. In these situations a patient
may be referred to a Level 2 doctor, for the purposes of initiating and stabilising the
patient on methadone. Once stabilised the patient can be re-referred to their own
Level 1 GP.
2.2 Level 1 GP Services
Once a patient has been stabilised at any of the locations outlined above, the patient
can be referred for ongoing methadone maintenance to a Level 1 GP. Ideally this
should be the patients’ own GP who is responsible for all the individual’s healthcare
needs.
2.3 Treatment Centres
The treatment centres provide methadone treatment through a multidisciplinary team
approach and are set up in geographical areas with a high prevalence of drug use.
Typically the Treatment Centres are large centres providing services to between 100
to 300 patients.  Prescribing and dispensing of methadone takes place on site. Doctors
working in these centres are usually GPs who are have a special interest and training
in substance misuse.
The Drug Treatment Centre Board (DTCB) at Trinity Court, Pearse Street, Dublin is
the largest treatment centre in the country managing in excess of 500 patients. It is
staffed by Consultant Psychiatrists and non-consultant hospital doctors training in
psychiatry as well as a full multidisciplinary team. The DTCB has a remit to manage
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patients with dual-diagnosis and difficult behavioural problems which require
specialist care. The majority of homeless patients are also managed in the DTCB.
2.4 Satellite Clinics
There are approximately 45 satellite clinics in the country servicing 20 to 50 patients
per day. Satellite clinics operate with full multidisciplinary teams and GPs
specialising in substance misuse. Satellite clinics operate in partnership with local
communities and are usually based on a parish catchment area.   Patients at these
clinics are normally dispensed their methadone in community pharmacies.
2.5 Inpatient Detoxification
In patient detoxification is available on a limited basis for patients who wish to
become drug free and detox from methadone. Currently there are a total of 26
detoxification beds available nationally through St. Michael’s ward in Beaumont
Hospital and Cuan Dara in Cherry Orchard. Other in-patient detox facilities are
available through non-statutory agencies and vary from region to region.
2.6 Rehabilitation Programmes
A wide range of rehabilitation programmes, both in-patient and outpatient, are
available for patients wishing to avail of these services. In most centres, patients must
be methadone abstinent before admission. However a small number of units offer a
short detox as part of the rehabilitation programme. Details of local services are
available through your HSE Addiction Co-ordinator. Appendix B.
3 Research and Development
The National Advisory Committee on Drugs was first established in 2000. Its role is
to advise the government in relation to prevalence, prevention, treatment,
rehabilitation and the consequence of drug use in the Irish and international context. It
also has a remit to commission relevant research into drug use in Ireland.
The Drug Misuse Research Division (DMRD) of the Health Research Board collects
annual statistics on all people presenting to drug treatment services. Statistics
regarding all drugs abused by presenting patients are captured and these allow for
more accurate planning in terms of services development nationally. The DMRD also
provides a library facility, which is available to all GPs7.  The library has all relevant
drug dependency journals as well as electronic data search.
The Central Treatment List (CTL) is a database of all patients who are currently or
who have ever been on methadone treatment. Under the 1998 Methadone regulations,
it is a legal requirement for all patients in receipt of methadone treatment to be
registered on the CTL. Access to the database is restricted to doctors and pharmacists
participating in the MTP.
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Chapter 2        Aims & Objectives of Treatment
The treatment of opiate misusers aims to improve the physical, psychological
and social health of individuals by:
• Minimising all harm associated with opiate misuse
• Reducing the health risks associated with illicit drug use, particularly the risk
of HIV, hepatitis B and C, and other blood-borne infections.
• Improving the overall personal, family and social functioning of the individual
• Stopping or reducing the use of illicit or non-prescribed drugs by the
individual.
• Facilitating and fully supporting patients in achieving a life free of drug
dependency while recognising that this may not be achievable for all
individuals.
• Prescribing safely, which helps reduce diversion of drugs into the illegal
market.
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Chapter 3 Assessment and Management Options
1 Initial Assessment
When a GP is approached by a patient who claims to be using illicit opiates it is
important for the GP to assess the patient carefully before considering how to
proceed. Initial management will depend on the level of training you have as a GP.
Level 2 GPs can do the following assessment and initiation of treatment. A Level 1
GPs should refer the patient to a more experienced colleague or a HSE clinic for
further assessment.
Management of the drug user begins at the initial consultation and a full
assessment may need to take place over 2-3 consultations. Urine screening is an
important part of this assessment; three urine screens over three separate consultations
should be taken.
Having confirmed patient’s identification the Key Points of assessment are:
1.1 Explore realistic goals with patient
• To stop or reduce illicit drug use.
• To reduce or stop frequency of injecting.
• If the patient continues to take drugs, encourage use for relief of
withdrawal symptoms rather than to get intoxicated.
• Review alcohol or other drug consumption if relevant.
• Where possible patients should be encouraged to stop using
benzodiazepines while cautioning against abrupt cessation of treatment.
• To begin to tackle other problem areas e.g. legal, financial,
accommodation and relationship problems.
• Regularise lifestyle e.g. attending appointment on time.
• Attend an addiction counsellor as appropriate.
1.2 Discuss practice policies
Drug users respond best to care and concern on the one hand and firm and consistent
boundaries on the other.  In order to provide such boundaries, practices may benefit
from an agreed written policy about working with drug users.  Policies relating to
appointments, prescriptions, medication and behaviour should be clearly stated in the
practice agreement.  It is useful to involve your practice staff in discussions about the
formulation of such a practice policy. See sample agreement Appendix C.
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Use of policies and agreements may enhance the doctor/patient relationship.
However, it can be inappropriate for the doctor to apply policies rigidly in all
circumstances.  ‘Flexible rigidity’ describes an approach that seems to works best
with this patient group.  It may be useful to indicate to the patient if there are any
conditions where flexibility will not be exercised, such as acts of violence, abuse of
staff etc.
1.3 Take a drug history including, medical, psychiatric, forensic and social
history
Making decisions about the treatment of individual patients has to be based on a
thorough assessment of what will work for that person.  This assessment should
include a detailed drug history, along with a full medical, psychiatric, forensic and
social history.  An assessment should also include a relevant physical examination
and urinalysis. There are a number of standardised assessment forms available which
may be helpful in documenting the relevant points when taking the history.
A sample assessment form detailing relevant history is available at
Appendix D.
1.4 Assess the presence of dependence
Before starting any type of methadone treatment it is necessary to confirm that the
patient is taking opioids and to establish the presence and severity of opiate
dependence.  The ICD10 are the internationally accepted criteria for establishing
dependence.
Quick Reference to ICD10 Criteria:
Physical
• Withdrawal manifested by the characteristic withdrawal syndrome or by the use of
the substance to relieve or avoid withdrawal symptoms.
• Tolerance is defined by either increased amounts used to achieve intoxication or
other desired effect or diminished effects with continued use of the same amount of
the substance.
Psychological
• Difficulty in controlling substance use; unsuccessful attempts to cut down or taking
the substance in larger amount over a longer period than intended.
• Continued substance use despite awareness of negative consequences of drug use.
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1.5 Explore patient’s expectations and their reasons for presenting at the
time
The patient may be:
• Motivated to change behaviour
• Suffering from mental illness
• Pregnant
• Due in court
• Referred from Drug Court
• Referred by a social worker
• Seeking advice about the effects of the drug they were taking
• Have had a recent health risk or have anxieties over their drug taking
• Brought for treatment by a concerned parent or friend
• No longer be able to source their drugs
• Referred from another Medical Practitioner
2 Urine Screening
Patients are asked to provide a fresh (preferably supervised) specimen of urine as part
of their initial assessment. Where supervision is not available temperature jars are a
useful substitute.
Remember:
• As a general rule, 3 urine samples, separated by at least 3 day intervals
should form part of the initial assessment and be completed prior to
commencing a patient on methadone.
Social
• A great deal of time spent in obtaining the substance, using the substance, or
recovering from the effects of substance use.
• Neglect of important social, occupational, or recreational activities.
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• The doctor should be satisfied as far as is possible that the sample is from
the patient being assessed preferable by supervising the sample.
• Urine screening is not a substitute for clinical assessment of the patient.
A full drug screen tested by the laboratory is recommended prior to commencing
methadone treatment.   On the spot testing may be done with a dipstick test (available
through your local treatment service). If heroin has been taken within the previous 72
hours, urine toxicology should be positive. It does not however indicate what quantity
has being taken.  Heroin may be detected up to 7 days in urine after ingestion
however it is usually excreted in 3-4 days.
See Excretion Times Appendix E.
3 Management Options
3.1 General management principles
Having made the initial assessment the doctor should decide on the most appropriate
treatment option for the patient. Your practice circumstances may dictate to some
extent the management options.  A guide to management is as follows:
If a patient has a small heroin habit:
e.g.: < 2 bags heroin daily
                               is smoking only
                               Using for a short time: < 3-6 months of daily use
Consider:
• Abstinence may be achievable in patients with a short history of heroin
use
• Some patients may achieve abstinence without the need for substitution
therapy.
• Symptomatic relief may be useful as an initial option in these cases (see
section on self-detox).Encourage symptomatic detoxification unless this
has already failed on previous occasions.
• If pharmacological intervention needed, consider short-term methadone
stabilisation followed if possible by reducing doses.
If a patient has an established heroin habit:
                    e.g. >2 bags heroin daily
                                 Smoking and/or injecting
                           Using for >6 months of daily use
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Consider:
• Methadone stabilisation is generally the preferred option
•  Following stabilisation methadone maintenance and/or methadone reducing
doses as agreed with patient.
Remember:
• Not all patients are suitable for treatment in primary care. Caution should be
exercised where a patient has:
• A history of violence
• Is cross addicted to alcohol, benzodiazepines or other substances
• A history of psychiatric illness
If you consider the patient unsuitable for treatment in primary care, refer to the
nearest addiction treatment service for further assessment
• Counselling and rehabilitation as an outpatient or inpatient should be offered
and made available to all patients as appropriate.
WARNING!
It is recommended that benzodiazepines and codeine or morphine based
medications are not prescribed to opiate dependent persons to assist with the
withdrawal syndrome. There is no evidence to support their use as being helpful
to the patient. There is a high risk that this medication will be abused and/or sold




Some people achieve abstinence through self-detox commonly known as going “cold
turkey” or going through “sickness”. It is important to reassure the patient and their
family that “cold turkey” is not in itself dangerous albeit very uncomfortable.
Withdrawal symptoms include:
• Flu like symptoms
• Myalgia
• Nausea and diarrhoea
• Piloerection
• Runny nose and sneezing
• Dilatation of pupils
• Insomnia
The most reliable and objective signs of opiate withdrawal are tachycardia and dilated
pupils.
The severity of withdrawal symptoms are often not directly related to the quantity of
drugs previously consumed. Many other factors including emotional issues
2 Symptomatic Detox
The withdrawal process may be assisted by the short term prescription of other drugs
to reduce withdrawal symptoms.
Consider medications such as:
• Non steroidal anti-inflammatories or paracetemol for muscle aches and pains.
• Antidiarrhoea agents such as loperamide 2mg up to five times daily.
• Anti-emetics such as metoclopramide or prochlorperazine 5mg tds.
• Mebeverine tds for stomach cramps.
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• Sleep disturbance is a common problem encountered in withdrawal.  This can
take time to settle but patients should be advised that the sleep difficulties will
resolve over time. Benzodiazepines should be avoided in this situation
however if a patient is very anxious or agitated benzodiazepines can be
considered but for short term use only.
For some individuals who undertake a symptomatic detox, general support,
encouragement and an understanding of the symptomalogy may help them to be
successful.
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Chapter 5 Methadone Treatment
1      Evidence base for methadone treatment
Methadone is currently the only opiate substitute treatment available in Ireland. This
is a well established treatment which has been available internationally for many
years and which has a strong evidence base for its use. Methadone is a synthetic,
orally active substance with properties similar to those of morphine. It was developed
during World War II and since that time has been thoroughly researched as a
substitute medication for opiate withdrawal syndrome.
In the Irish setting the 1mg/1ml sugar-free formulation of methadone is the only one
available. It has a long half-life of up to 36 hours and therefore can be taken once
daily. It is absorbed from the gastro-intestinal tract and reaches peak concentration at
about 4 hours. It is metabolised by the liver and therefore drugs which induce liver
enzymes (e.g.rifampicin, phenytoin, carbamazepine) may reduce the clinical effect of
methadone. Similarly, enzyme inhibitors (e.g.cimetidine) may potentiate the effects of
methadone.
Methadone is a mu receptor agonist. Pharmacodynamic interactions may involve the
potentiation of opioid effects by other opioid agonists. Opioid antagonists such as
naloxone or naltrexone reduce the opioid effects of methadone. Interactions which
may potentiate the CNS stimulant effects or the respiratory effects of methadone
include alcohol, anti-psychotic, tricyclic antidepressants or benzodiazepines.
Concurrent use of these substances should therefore be avoided.
The benefits of substitute prescribing with methadone are:
• Improvement in health and social functioning.
• Reduction in opiate related deaths.
• Reduction in illicit heroin use.
• Better retention in treatment.
• Reduction in criminal activity.
• Reduction in transmission of HIV.
• It is cost effective.
The benefits of methadone have a strong evidence base and a number of
comprehensive literature reviews support the above findings8.  The 5-year follow up
of the National Treatment Outcome Research Study (NTORS) in the UK, which
monitored the progress of 1075 clients recruited into either residential or community
treatment services over five years, also supports the findings as above9.
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Taken together over two decades, the randomised studies of methadone maintenance
demonstrate consistent, positive results over vastly different cultural contexts. If
practitioners are properly trained, methadone maintenance can be effectively and
safely delivered in a wide range of settings, including primary care.
In 1993 ACMD (Advisory Committee on Methadone Dispensing, U.K.) concluded
that:
“The benefit to be gained from oral methadone maintenance programmes both in
terms of individual and public health and cost effectiveness has now been clearly
demonstrated and we conclude that the development of structured programmes in the
UK would represent a major improvement in this area of service delivery.”
2 Commencing and Stabilising on Methadone Treatment
The commencement dose should aim to achieve an effective level of comfort, both
physical and psychological, while minimising the likelihood of overdose. In deciding
on a starting dose:
• Assess average daily intake of illicit drugs from drug history.
• Start on a low dose i.e. not greater than 30mg daily and work up. This
minimises the risk of overdose.
• If tolerance is low e.g. in someone with a small or recent habit,10-20mg may
be more appropriate.
• Increments should be no greater than 10mg at a time.
• Increments may be made until, there are no physical withdrawals and illicit
drug use has ceased. Higher doses may be required to eliminate cravings.
• Do not continue to increase the dose if there are signs of intoxication.
• It may be that the patient continues illegal drug use because the dose of the
methadone is not sufficient.
Stabilisation doses must be determined individually because of differences in
metabolism and body weight. Patients usually stabilise on doses between 60mg to
80mg. However some patients can stabilise on lower does particularly if their habit is
small. While lower doses may relieve signs and symptoms of withdrawal, higher
doses may be required to obliterate cravings. Adequate doses of methadone will block
the euphoric effects of heroin.
Higher doses of methadone (>80mg) may be required in patients who are on
concomitant medication which induce enzymes involved in methadone metabolism.
Typically this includes anti-retroviral and anti tuberculosis medication, which usually
reduce serum methadone levels by 50% requiring a similar dose increase.
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Remember:
• It is important to note that commencing a methadone programme can be
a risky time for patients as tolerance is uncertain at the early stage of
treatment.
• Level 1 doctors should not increase patient doses without seeking advice
from your GP Co-ordinator.
• If a patient requires a dose > 80mg and you have limited experience of
treatment consider consulting with your GP co-ordinator for advice.
3 Dispensing Instructions for Methadone
There are two considerations when methadone dispensing arrangements are being
made:
• Safety of the individual patient
• Safety of other patients
• Avoiding street diversion of methadone
Supervised consumption of methadone is recognised as an important element in the
delivery of methadone treatment services because it:
• Reduces the risk of a patient ingesting in excess of their recommended dose.
• Reduces the risk of the patient diverting their methadone to other persons or
the illegal market.
In the initial stabilisation phase it is recommended that:
• Consumption of methadone should be supervised daily.
If a drug user is making satisfactory progress on the programme and you are clinically
satisfied that the patient can safely manage their own dosing, the dispensing intervals
can be gradually increased to three times weekly, then twice weekly, then weekly.  If
the patient destabilises, return to more frequent dispensing is recommended. All
patients should remain on at least once weekly supervision
Greater caution in allowing take home doses should be exercised where there is
suspicion of alcohol abuse, benzodiazepines or other substance abuse.  The rationale
for this is a safety one. The co- abuse of alcohol or benzodiazepines increases the risk
of fatal overdose by potentiating the risk of respiratory depression.
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If a pharmacy does not have the facility for supervised consumption this should be
brought to the attention of the GP co-ordinator or the liaison pharmacist if this is the
case.
Once stable, it is currently recommended that:
• At least one dose per week is supervised in the chemist.
The rationale for this is that it minimizes the risk of the patient reducing their
prescribed dose and diverting methadone onto the black market. This policy needs to
be carefully explained to the patient as they may be exposing themselves to the risk of
overdose on the day of supervision due to reduced tolerance.
• No more than one week’s methadone should be dispensed at one time
except for holidays. (See special dispensing arrangements)
There are additional risks of street diversion of methadone when methadone is
dispensed in large amounts.
Exceptions to this may be:
• Stable patients on very low doses (e.g. < 15mls) may not need supervision.
• Higher doses (>80mls) are potentially more dangerous if given in large
take away doses. It may be prudent to have twice weekly supervision in
such cases.
Remember:
• It is necessary to specify on the Methadone prescription what level of
supervision is required i.e. every day, alternate days etc. There is a special
section on the Methadone script where this can be specified.  To minimise
inconvenience for the patient, consumption should ideally be supervised
on the day the patient attends the pharmacy with his/her script.
See examples of Methadone Prescription Forms Appendix F.
The pharmacist is a very valuable member of the care team. Regular communication
with the patients’ pharmacist should be encouraged as the pharmacist may often have




• All doses supervised until patient stable
• Minimum of one dose supervised weekly even if patient stable
• Caution with doses > 80mls daily: consider twice weekly supervision
4 Detoxification and Methadone Reduction Regimes
Stability on methadone offers the opportunity to improve the overall personal, family
and social functioning of the individual.  It may take months or even years for a drug
user to reach the stage where a reduction in their methadone can be considered.
Treatment options should be regularly reviewed with the patient and realistic gaols
set, which will maximise the patient’s health.
All dose reductions whether detoxification or slow reductions, are unhelpful if
imposed by the prescriber. A reduction in dose should always be negotiated with the
individual drug user; if imposed it can lead to a return to street drugs, unsafe injecting
and a sense of failure for the patient.  The patient needs to feel safe, comfortable and
ready to reduce their dose before attempting to do so. It can often cause anxiety for
the drug user therefore reassurance that treatment will be available if reduction is
unsuccessful is important. There are two types of approaches towards abstinence:
detoxification over a defined period or slow dose reductions over months or even
years.
4.1 Detoxification
Detoxification is defined as opiate withdrawal which takes place over a defined period
of time. Detoxification can take place safely on an outpatient or an inpatient basis.
While the overall success rate for detoxification is low, especially at the first attempt,
certain criteria can enhance the possibility of success. Careful assessment using the
following criteria is essential.
Opiate detoxification is more likely to be successful if there is:
• Strong patient motivation.
• Good psychosocial support.
• Psychosocial stability.
• A defined after-care plan.Places for inpatient detoxification are limited and in
most instances should only be considered if the patient has tried a supported
community detox in the first instance.
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4.2 Slow Reduction of Methadone
For many patients achieving stability on methadone is their first goal. Having reached
a level of stability and where there is good psychosocial stability, the patient may
wish to consider working towards abstinence by slowly reducing their methadone
dose over time. There is no formal evaluation of this approach but clinical experience
would suggest that:
• Flexible, separately negotiated dose reductions are best.
• Start with small reductions; large reductions are more likely to fail.  See
Summary.
• Further reductions can follow when the drug user feels confident and stable on
the new dose.
• A return to the previous dose level may be necessary if the drug user does not
cope with the initial drop in dose. However dose reduction can be tried again,
perhaps in smaller steps.
Advantages of this approach
• Reductions can be planned to take account of other circumstances in the drug
user's life.
• Each successful small step will help to reinforce progress and boost the drug
user's self esteem.
• The drug users will be able to focus on small reductions rather than feeling
anxious about eventually having to cope without drugs.
• The drug user is more likely to succeed in eventually getting off drug and
staying off.
Remember:
• It is usually too difficult for patients to try to reduce from both
methadone and other drugs at the same time.
• If patient taking more than one drug, aim to reduce one drug at a time.
Benzodiazepines ideally should be reduced first once the patient is stable
on their methadone.
• Before attempting to reduce their methadone dose the patient should be
stable on that dose and not abusing other drugs.
• Many patients may never be able to achieve total abstinence. It is
important that all reductions are by negotiation
22
Summary: Methadone Reductions
The dose reductions outlined here are for guidance only; negotiate individual
reductions with the drug user.  In general, reductions of between 5-10% of the
current dose is recommended depending on the individual patient.
Example:
              If stable on more than 100mgs methadone
-  Reduce by 5-10 mgs at a time
              If stable on 40 - 90mgs methadone
            -  Reduce by 5mgs at a time
              If stable on 20 - 40mgs methadone
            -  Reduce by 2-5mgs at a time
              Below 20mgs methadone
            -  Reduce by 1-2 mgs at a time
5 Monitoring and Review
Drug users on methadone should be seen regularly for review. For most stable
patients this is a weekly review. The frequency of the review however, will
depend on the stage of their treatment programme:
• At the start of their programme when the methadone dose is being
determined, the patient should attend daily at their pharmacy or clinic and
should be reviewed if possible twice weekly by their doctor.
• Once stable i.e. urines samples are negative for opiate, a weekly review by
their doctor may be appropriate. Daily dispensing of methadone should
however continue until the patient is stable usually for about three months.
• Patients stable on methadone for a period of one year with urine samples free
from illicit drugs may be seen fortnightly if it is considered clinically safe to
do so.
More frequent review may be appropriate if drug user:
• Is continuing to use illicit substances
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• Is chaotic in their behaviour e.g. running out of medication early, missing
appointments
• Has ongoing medical or mental health issues
• Is undergoing dose adjustment (either up or down)
Regular patient review should include a discussion with the patient around adequacy
of dose, additional drug use, psychosocial issues and a urine screen. Urine is currently
the most reliable body fluid for drug screening purposes. Where possible, the urine
sample should be directly supervised. However in the primary care setting this may
not always be possible for logistical reasons. In these situations all reasonable
precautions should be taken to ensure the integrity of the sample e.g. check
temperature of sample by having a temperature strip on the urine jar; no coats or bags
allowed into toilet; pockets checked or emptied before entering toilet; laboratory
testing for methadone metabolites and creatinine. If urine sample results are required
for forensic purposes, it is necessary to have more rigorous testing procedures.
6 Destabilisation
It is not uncommon for patients who have been doing well on methadone treatment to
have relapses to illicit drug use. Often this will involve isolated incidents. If relapse
continues for any length of time the patient may re-experience the difficulties
associated with chaotic drug use.
This process of destabilisation may occur as a result of some trauma or set back in the
patient’s life. Sometimes it may be a gradual deterioration with no obvious cause.
Destabilisation can be caused by a number of factors:
• The perceived boredom of sobriety may cause patients to relapse.
• Stressful life events such as bereavement, court cases and relationship
problems.
• Sometimes changes in treatment location may lead to the return to drug use.
• Onset or relapse of a psychiatric problem or illness.
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Risks associated with destabilisation include:
• Re-exposure to the risk of viral diseases.
• Relapse to criminal activity.
• Relapse to chaotic lifestyle.
• Deterioration in family relationships.
6.1 Managing a patient who has destabilised
A doctor who is seeing a patient weekly may notice a change in that patient if they are
destabilizing. The early signs of destabilisation may be:
• Opiate positive urinalysis.
• Missed appointments or late attendance at appointments.
• A change in mood or demeanour.
There are a number of strategies, which offer the patient increased support during a
period of destabilisation. It is important to explain to the patient that any changes in
their management are designed to be supportive rather than punitive.
• Methadone dosage may need to be increased if the patient has been using
heroin on top of their normal methadone dosage.
• Increase the surgery attendance.  To encourage attendance, prescriptions can
be written twice weekly during a period of instability.
• Urine testing may be increased in frequency to give a more accurate picture of
the patient’s drug taking.
A period of destabilisation may, once resolved, present an opportunity to encourage
the patient to consider the “bigger picture” of their addiction. Patients should be
offered referral to counselling or rehabilitation services.
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Remember:
• Destabilisation does not automatically require re-referring a patient to a
clinic. However, if a GP feels that the behaviour of the patient is becoming
too difficult or it is unsafe to continue treatment of a patient in a
community setting, they should contact their GP Coordinator. Under the
terms of the Methadone Treatment Protocol the HSE agrees to transfer
unstable, difficult or abusive patients from the community to treatment
centres immediately if necessary.
• It may be helpful to share case histories of difficult clients with other
colleagues.  Even the most experienced GP’s may have difficulties in
managing individual clients.
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Chapter 6 Special Groups and Substitute Prescribing





Only Level II GP’s who have access to adequate psychosocial supports should initiate
treatment in adolescents. A multidisciplinary team approach is considered best
practice when managing underage drug users.  Other team members should include a
drug counsellor, consultant child and adolescent psychiatrist, family therapist.
Interagency work with Social Workers, Probation and Welfare and Housing
Authorities is also important aspect of working with adolescents. Engaging the
support of the young persons family whenever possible is desirable.
1.1 Parental Consent
The Offences against the Person's Act 1997, empowers 16 years old and older
adolescents to give consent to medical treatment.  This however is modified by the
Constitution, which enshrines the right of moral guardianship of an adolescent, (under
the age 18) to the parents and is further modified by the ability of the adolescent to
understand the nature of the treatment and the risks involved. Therefore even if an
adolescent is capable of consent it is strongly advised that parental consent is obtained
before substitute prescribing is commenced in 16-18 year olds. Without such consent
a second opinion of a GP Co-ordinator should be sought.
1.2 Treatment
If substitute prescribing is considered appropriate for a particular adolescent, it ideally
should be for as brief a time as possible. The aim, where practicable, should be to
reduce or detoxify once the adolescent is stabilised and is no longer involved in
harmful drug use. However, a balance needs to be struck between continuing
treatment and the risks of ongoing drug misuse. Methadone maintenance is unlikely to
be the first treatment of choice for most adolescents with opiate misuse problems.
However, if there is a clearly defined opiate dependence and if other interventions
have failed, longer term substitute prescribing may be the most appropriate
intervention for an individual.
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Remember:
• The induction phase of treatment should be taken more slowly than with
adults because tolerance is usually lower in the adolescent.
2 Pregnancy in Opiate Dependant Women
Treatment of opiate dependant women has been shown to have positive influences on
pregnancy outcomes10.  Women attending treatment services have better antenatal
care and better outcomes in terms of childbirth and child development11.
Liaison midwives appointed by the HSE, work in the three Dublin maternity
hospitals. Their role is to provide a link between drug treatment services, maternity
services and hospital social services. It is important to refer the patient to the liaison
midwife as early as possible on entering treatment.
Drug stability while on treatment is important in terms of pregnancy outcomes.
Patients who continue to use heroin and fail to stabilise should be offered admission
to an inpatient unit for stabilisation.  If a woman wishes to detoxify during her
pregnancy this can be offered on an out- patient or in-patient basis. It is recommended
that detoxification in the middle trimester may be safest as there is a higher risk of
miscarriage in the first trimester and premature labour in the third trimester.
Most mothers remain stable during pregnancy and are very capable parents.  Some
mothers who use drugs chaotically during pregnancy may have difficulty in parenting.
Social supports may need to be put in place and the situation monitored by social
services. These responsibilities are clearly outlined under ‘Children First’
(Department of Health, Ireland, 1999)12.
As with all pregnant women, any prescribed medication should be reviewed at the
earliest opportunity. Nicotine, alcohol and benzodiazepine consumption should be
given special consideration in opiate dependant pregnant women.
There is evidence of increased risks of miscarriage, intra-uterine growth retardation
and pre-term deliveries in drug using women. These effects are multifactorial and are
common in woman from the lower-socioeconomic groups and those who smoke.
Specific illicit drugs have been shown to have some specific effects e.g .maternal
cocaine use increases the risk of placental abruption, stillbirths and sudden infant
death syndrome. Heroin has been shown to cause low birth weight babies and
premature delivery.
Remember:
• Attracting and maintaining pregnant women in treatment is therefore
important and should always be prioritised.
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2.1 Breast-feeding
Breast feeding should be encouraged in the usual way even if a mother is taking
methadone. Breast feeding is contraindicated in HIV positive patients. It is not
contraindicated in Hepatitis C positive people or patients with any other form of
hepatitis.  Specialist advice is available for mothers who are HIV or Hep C positive.
2.2 Neonatal Abstinence Syndrome
Neonatal Abstinence Syndrome (NAS) occurs to a greater or lesser extent in most
babies born to opiate dependant women.
It is characterised by:
• Irritability and poor sucking reflex.
• Gastrointestinal symptoms, respiratory difficulties.
Treatment includes supportive swaddling, frequent small feeds and no sudden
movement.  Pharmacological treatment when indicated is usually with oral morphine
or in rare severe cases with phenobarbitone.
There is no direct correlation between methadone dose and NAS. There is a
suggestion however with doses less than 40mg the risk of NAS is reduced as long as
no other substances are being abused.
The use of benzodiazepines during pregnancy may cause neonatal withdrawals. Their
use can cause delayed onset and prolongation of neonatal withdrawals. Symptoms of
abstinence may occur at 7-14 days sometimes after the baby has been discharged from
hospital.
3 Psychiatric Co-morbidity or Dual Diagnosis
There is a significant incidence of mental health problems in opiate dependent
patients particularly anxiety and depression. It is recognised that in excess of 50% of
illicit drug users and in excess of 60% of alcohol abusers have a dual diagnosis.
Significant improvements in psychological well being have been shown when patients
engage in drug treatment. There is evidence of improved overall social functioning
when the underlying mental health problem is managed in conjunction with their
substance abuse problem. Care planning and multidisciplinary team work is essential
with this particularly vulnerable patient group.
3.1 Depression
Depression is common in the drug using population and this should be assessed and
monitored closely. Patients who require antidepressants should be prescribed S.S.R.I.s
where possible. Tricyclic antidepressants (particulary Dothiepin) should be avoided,
as there is a high incidence of abuse in the Irish context.
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Managing drug dependent patients who have concomitant severe mental health
problems can be very challenging in the primary care setting. It may be appropriate to
refer such patients to a Drug Treatment Centre where there is access to regular
psychiatric evaluation. Hospital admission may be required in the some cases,
particularly patients at risk of suicide.
3.2 Anxiety/Paranoia
Stimulants such as cocaine ecstasy and amphetamines are a significant cause of bith
anxiety and paranoia. However any drug if used to excess can cause these symptoms.
There is now increasing evidence that cannabis use in vulnerable individuals can
cause these symptoms and in some instances may unmask an underlying risk of
schizophrenia.
Remember:
• Patients with significant mental health issues or who have a past
psychiatric history should be prioritised for treatment.
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Chapter 7 Drug Related Deaths and Overdose
Drug Related Deaths is an important issue which has been highlighted at the World
Health Organization (WHO) and at the European Monitoring Centre for Drugs and
Drug Addiction (EMCDDA) as being one of the main consequences of drug use and a
major cause of death in young people. Drug related deaths have been identified by the
EMCDDA as being preventable in many instances.
People most at risk include:
1. Male drug users – (75%)
2. Drug users following detoxification
3. Polydrug users – (89% tested positive for more than one substance)
4. Drug users on entry to or on release from prison - 13%
5. Opiates used with alcohol and/or benzodiazepines contributed to many of the
deaths
6. Drug users using alone
In 2005 a working group was convened by the Irish College of General Practitioners
Drug Misuse Programme to examine the issue of drug related deaths in Ireland.13
The report makes recommendations which, if implemented could prevent many drug
related deaths.  These conclusions of the report are that:
• Treatment providers should identify high risk individuals.
• Risky behaviours and situations should be addressed with the individual.
• Education around overdose prevention is important for high risk individuals
and referral to an outreach worker/addiction counsellor should be made where
appropriate
• Patients being initiated on methadone treatment are at particular risk of
overdose due to the cumulative effects of methadone, ongoing use of heroin
and low/unknown tolerance. Increasing the dose slowly during the induction
phase of treatment helps to ensure that the prescribed methadone dosage does
not exceed the tolerance level, particularly when other drugs such as
benzodiazepine and alcohol are being used.
• Once on methadone treatment the GP should minimise the risk of diversion of
prescribed methadone by arranging supervised consumption. Take away doses
should ideally not be provided until patient stable and in most cases for a
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period of three months after commencing the programme. When patients are
receiving take away doses they should be informed about the safe keeping of
methadone i.e. out of reach of children and others.
• Fatal overdose in methadone maintained patients most commonly occur when
other drugs such as benzodiazepines and alcohol are being abused. Tricyclic
antidepressants, cocaine and heroin are also implicated in overdose if being
abused.
• All drug users undergoing detoxification, in both outpatient and inpatient
settings should be made aware of the risks of overdose particularly following
detoxification.  Patients should be requested to consent that they have been
informed of the overdose risk associated with detoxing.
• On release from prison, tolerance may be lessened and a patient who resumes
the level of heroin use as previously (when their tolerance was higher) may be
at risk of a fatal overdose. All known drug users should therefore be facilitated
with an early appointment with their GP. This is particularly important for
drug users who are not on methadone treatment as they are considered a
higher overdose risk.
• Opiate naïve persons may acquire methadone for occasional recreational use
and are at serious risk of fatal overdose.
Remember:
• Signs of toxicity/overdose range from slight drowsiness to respiratory
depression, coma and death.
• Naloxone 1mg/ml should be readily available in all practices providing
drug treatment for use in cases of opiate overdoses. Practices should have
emergency resuscitation facilities available and be trained in Basic Life
Support (BLS)
WARNING!
Overdose risk following detoxification.
As opiate tolerance will be reduced following detox, it is important to warn
patients of the risk of overdose should relapse to heroin use occur following a
period of abstinence.
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Chapter 8 Problem Section
The problems listed are ones which present from time to time in the management of
opiate users on the MTP.
1. Missing the Chemist
2. Giving False Urine Samples
3. Special Dispensing Arrangements
4. Needle –stick injuries
5. Drug driving
1 Missing the Chemist
Patients miss their dose at the chemist for many reasons. If there are practical reasons
why a patient is missing the chemist e.g. opening hours, work commitments or
distance to travel, this should be addressed as soon as possible with a view to making
alternative arrangements for dispensing.
Missing the chemist may also be a sign of chaos or destabilisation.
A patient who misses 1 day of methadone may not feel any withdrawals due to the
long half-life of methadone. By the second day most patients will be experiencing
withdrawals and in some cases will resort to heroin to deal with this.
If a patient has missed 2 consecutive days at the chemist it is recommended to:
• Review the patient as soon as possible
• Review a patient’s dose of methadone
• To reduce their dose to 30mg or half their previous dose to minimise the
risk of opiate overdose.
• After restarting the patient at a lower dose their dose should be titrated
upwards, increasing at no more than 10mg methadone every day.
• The community pharmacists should be made aware of this policy in advance.
In some situations it may be acceptable to discuss the patient’s condition with the
pharmacist if it is not practicable to review the patient in person. However the
clinician should be satisfied that whatever action is taken does not put the patient at
risk of overdose.
Remember:
• The pharmacist should always inform the GP if a patient misses a dose.
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2 False Urines
It can be difficult to know when someone is giving a false urine. Directly supervising
the urine or using temperature urine bottles may overcome this. Other practical
alternatives to direct supervision which may suit some practices include emptying all
pockets, leaving jackets, bags etc in consulting room prior to giving sample.
Patients may be tempted to provide a false urine sample for a variety of reasons:
• They may be continuing to take heroin
• They may be taking another substance and may not wish to disclose this.
• They may not be taking methadone as prescribed.
• To maintain a good urine record for the purposes of court.
• They may not want to disappoint the doctor.
By far the commonest reason for the false urine is heroin or other illicit drug use.
Some patients may provide a false urine because they have not been taking their
methadone dose as prescribed.  In this scenario they may be diverting or selling their
methadone.  This can have serious consequences with regard to the patient’s tolerance
and the risks need to be highlighted with the patient. Management of this situation
should be discussed with the GP co-ordinator, as each situation may be managed
differently.
3 Special Dispensing Arrangements
All efforts should be made to ensure that a patient on a maintenance script does not
have their treatment interrupted unnecessarily. Circumstances, which may cause a
change to normal arrangements, are:
3.1 Public Holidays and Bank Holidays
Special provision for Christmas, Easter and bank holidays may be required depending
on local dispensing arrangements. Discuss the opening hours of the pharmacy in
advance and negotiate take away doses with the patient. The number of take away
doses will depend on the patient’s level of stability
3.2 Holidays
At the commencement of treatment all patients should be made aware of dispensing
arrangements for periods of travel. The patient should provide proof of travel in
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advance which allows time for any special arrangement to be made with the
pharmacist. It also provides an opportunity to discuss issues around safe carriage and
use of methadone while away.
There are currently no restrictions or legal requirements regarding carrying
methadone for one’s personal use. It may be prudent however to provide the patient
with a letter confirming it is for personal use. If the patient is travelling for an
extended period of time involving large quantities of methadone, it may be necessary
to arrange treatment with a prescriber abroad.
Take-away doses may be provided for a holiday period provided a patient is stable
and capable of managing a take away dose safely. When a patient is not stable, careful
consideration should be given before allowing patient take away doses. It is at the
discretion of the prescriber whether he/she feels it is safe to give the patient take away
doses however, ultimately it is the patient’s responsibility to take their medication
safely.
Remember:
• Current restrictions on carrying liquids in hand luggage is limited to
100mls. Patients should be reminded of this restriction prior to travel.
There is no restriction on the amounts carried in checked in luggage.
3.3 Prison
Methadone treatment as delivered in the Prison Service is beyond the scope of this
document. However as there are maintenance programmes in some of the prisons, a
patient can now continue their treatment if they find themselves detained. Ideally
there should be no interruption to treatment on admission or discharge from prison.
In practice this is not always the case and strenuous efforts are being made to improve
the system. Inter-agency communication is vital if unnecessary interruptions to
treatment are to be avoided. On entry to prison, a letter from the treating GP outlining
current clinical and virology status should be sought by the prison services. Also, on
release, confirmation of continued treatment while in custody and other relevant
details should be forwarded to the patient’s GP.
3.4 Hospital
Patients should be continued on their methadone treatment while in hospital unless
there are medical grounds for stopping it. It is more common for patients to be
admitted to hospital with complications of their drug use due to non compliance with
their treatment programme. In most cases treatment will be re-commenced in this




Needle stick injuries are rare but can happen as a result of any of the following:
• Accidental injury during phlebotomy or disposal of sharps
• Assault/mugging with a syringe and needle
• Inoculation of an open wound
The risk is dependent on the degree of penetration and the amount of blood
inoculated.
The risk of transmission for blood borne viruses following a needlestick injury:
Hepatitis B    = 30%
Hepatitis C    = 1.8%
HIV    = 0.3%
4.1 Hepatitis B
Hepatitis B has the highest risk of transmission following needlestick injury but is
eminently preventable. All health care workers should be fully vaccinated. The risk to
a fully immunised worker who has shown an adequate immune response is virtually
zero.
Any non-immune person exposed to hepatitis B virus should be given hepatitis
B immunoglobulin prophylaxis as soon as possible. This should be done preferably
within 48hours but not later than one week after exposure. An accelerated hepatitis B
vaccination programme should then be commenced.
4.2 Hepatitis C
The risk of hepatitis C is increasingly problematic due to the high prevalence in the
drug using population. There is currently no vaccine or immunoglobulin available.
4.3 HIV
Higher transmissions rates are likely following needlestick injury if the:
• Needle has been used intravenously
• Source person has a high viral load
• Penetrating injury is deep
• Needle is visibly contaminated with blood
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Remember:
• Re-sheathing needles remains a common and avoidable cause of needle
stick injury.
• Universal precautions should be adopted in all situations where blood
spillage may be likely.
• In the case of needlestick injury all patients should present to the nearest
hospital with an Infectious Diseases Department for appropriate
management.  The viral status of the source person should be ascertained.
Follow -up blood samples should be taken at 6 weeks and 6 months to
account for the “window period” for sero-conversion.
5 Drug Driving
The ethical issues surrounding whether or not a doctor should disclose information
regarding a patient who is driving under the influence of a substance are complex.
While the onus is on the licence holder to report use of any substance, prescribed or
otherwise, which may impair their ability to drive, doctors may find themselves in a
position where a patient is putting themselves and other road users at risk. In such
situations it is good practice to make the patient aware of your concerns and advise
them to stop driving until they are safe to do so. A thorough assessment of the risks
involved should be clearly documented in the patient record before a decision to
breach confidentiality is made. Before disclosing any information regarding an
impaired driver, it is advisable for the doctor to discuss the situation with their
medical defence organisation
The induction phase of methadone treatment needs particular attention with regard to
driving. It is prudent to advise patients that they should not drive while being
commenced on methadone treatment and until their dose is stabilised. This is because
the patient may feel sedated in the early stages of their methadone programme.
However, patients who are stable on a regular methadone dose and who are adhering
to a monitored programme are considered at low risk of being sedated and unfit to
drive.
All psychoactive drugs have the potential to impair driving. When combinations of
drugs are used (i.e. with other medications, with illicit substances or with alcohol) the
risks are further increased.
The complex issues surrounding drug driving will be addressed under action points
32,45,75,76,77 and 78 of the Road Safety Strategy 2007-2012 (www.rsa.ie)
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Chapter 9 Management of other Drugs of Misuse
Many patients who are addicted to heroin also regularly abuse other prescribed or
illicit drugs. If not currently using them they may well have used them in the past.











General principles of management include:
• Take a full history
• Assess whether the drug user acknowledges a problem
• Ask them to keep a drug diary
• Giving information about the effects and dangers of drugs
• Encourage them to reduce their intake by setting realistic goals together
• Explore any underlying problems
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1 Alcohol
Patients on methadone treatment commonly abuse alcohol. A number of factors make
this particularly high risk for drug users:
• Alcohol use in combination with methadone and other drugs increase the risk
of overdose
• There is lower retention in treatment when patients are also abusing alcohol
• High rates of Hepatitis C increase the risk of cirrhosis
The general principles of managing of patients with an alcohol problem remain the
same as the general population. The option of transferring a patient to a treatment
centre should be considered if the alcohol problem is unmanageable in the
community setting
For most patients inpatient detoxification for alcohol is not routinely required;
outpatient or home detoxification is often sufficient. For patients physically dependent
on alcohol, planned detoxification may be appropriate.
2 Benzodiazepines
This best practice committee endorses the Benzodiazpeine Report14 and the Good
Practice Guidelines for Clinicians15.
Benzodiazepine misuse is common in opiate users with one report suggesting 70% of
patients in treatment had benzodiazepine positive urine during the past month.16
Prescribing benzodiazepines for known opiate users should only be considered
if:
• Benzodiazepines are being taken daily – verified by presence in the urine.
However it is important to note that benzodiazepines may stay in the urine for
up to 6 weeks and it is difficult to quantify the amounts taken on a routine
screen. Benzo levels can be checked on request through the laboratory at the
Drug Treatment Centre Board17.
• There is convincing evidence of dependence following clinical evaluation (use
ICD10 criteria).
If in doubt discuss the case with your GP Co-ordinator before issuing a script.
When prescribing benzodiazepines, special consideration should be given to
patients on methadone treatment:
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• Consider daily dispensing of benzodiazepines if there are any concerns re
patient stability.
• If a patient is detoxing from their benzodiazepines, the methadone dose should
be kept stable throughout the reduction period.
• Concurrent detoxification in the community of both drugs is not
recommended.
Diazepam is the drug of choice for benzodiazepine maintenance or detoxification. It is
a good idea to convert all benzodiazepines to diazepam using the following
conversion chart:
The advantage of Diazepam is that it has a relatively long half-life and is available in
different strength tablets. The dose needs to be adjusted relative to withdrawal
symptoms. Commencement doses should not exceed recommended therapeutic dose.
There is no single best detoxification regime for benzodiazepines; discussion and
negotiation with the patient is imperative. Goals should be simple and attainable for
the patient.
In line with the recommendations of the Benzodiazepine Report patients on
benzodiazepine prescriptions should be regularly reviewed on at least a monthly basis
because of the long-term dependency effects. Regular communication between
prescribers for opiate users is essential (e.g. between treatment clinics and community
GPs) to avoid duplicate prescribing.
3 Cannabis
This is used extensively, especially in young people. It is generally considered not to
be a physically addictive substance (as in no defined physical withdrawal syndrome)
but patients may have a significant psychological dependence. Regular and extensive
use, especially if used throughout the day, may be associated with lethargy, low
motivation, depression anxiety and paranoia. There is increasing evidence regarding
links between schizophrenia and chronic, heavy cannabis use particularly with early
onset of use. There is no substitute treatment available for cannabis users. Addiction










people with mental health issues may self-medicate with cannabis and other
substances. A mental health assessment of these patients is very important.
4 Ecstasy
Ecstasy is a stimulant which is not physically addictive. If used extensively at the
weekends it may reduce performance during the week. Regular misusers sometimes
use heroin, methadone or benzodiazepines as a means to come down from ecstasy and
therefore risk becoming addicted to these substances. Rarely ecstasy can precipitate
psychosis. It may be associated with heat exhaustion, Disseminated Intravascular
Coagulation (DIC), renal failure, coma and death. This may not be related to the
amount ingested; it may be an idiosyncratic response to the drug. There is an
increased level of clinical depression in people who use ecstasy due to the
interference in serotonin metabolism.
5 Cocaine
Cocaine is a stimulant, which may cause significant psychological dependence. But
when used in a prolonged and substantial way may cause physical dependence. The
user may experience euphoria, increased energy, heightened sexual pleasure and
alertness.
Negative effects such as agitation, anxiety, panic attacks, loss of libido, insomnia,
labile mood, paranoia and hallucinations may also be experienced.
Cocaine is commonly snorted, smoked as crack, freebased or injected intravenously.
Cocaine use can be confirmed by urinalysis. There is no substitute treatment available
for cocaine dependency but counselling, the 12 step AA model, or cognitive
behavioural therapy may be useful.  Depressed mood is common in users coming off
cocaine and clinical depression should be looked for and treated as appropriate.
Peak concentrations are reached after 5 to 20 minutes when inhaled intra-nasally and
within seconds when smoked or injected. Intoxication is noted by dilated pupils,
tachycardia, tachypnoea and hypertension.
Medical complications include:
• Cardiac: arrhythmia, arrest and infarction
• CNS: seizures, stroke and subarrachnoid haemorrhage
• Deep vein thrombosis
• Vasculitis and vascular spasm
• Complications in pregnancy
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Necrosis of the nasal cartilage and septal perforation may occur when cocaine is
snorted.  When inhaled as “crack” or freebased, pneumothorax or pulmonary oedema
may occur.
When combined with alcohol, cocaine can be a particularly lethal drug. Cocaethylene
forms in the blood.
6 Amphetamines
Amphetamines are often used recreationally e.g. at weekend and maybe mixed with
other drugs such as ecstasy. They are not physically addictive but psychological
dependence is severe.
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Chapter 10 Blood Borne Viruses in Opiate Users
1 Hepatitis C
Hepatitis C (HCV) is the most common cause of chronic viral infection in the western
world.  First described in 1989, HCV is a single stranded RNA virus. At least six
genotypes have been identified worldwide but genotype 1 and 3 are commonest in
Ireland, United Kingdom and North America. Genotype 3 is currently more amenable
treatment than genotype 1.
All patients receiving drug treatment should have screening for Hepatitis C and
should be referred as appropriate.
• HCV infection in the drug using community in the Dublin area is widespread with
as many as 62 – 80% of intravenous drug users believed to be infected. Those
with active viraemia are infected with either genotype 1 or 3 in approximately
equal proportions.
• Diagnosis of HCV infection is by enzyme linked immunoabsorbent assay
(ELISA) testing looking for antibodies to HCV. This is confirmed by recombinant
immunoblot assay (RIBA). Active viraemia and thence infectiousness is
documented by the presence in the serum of HCV-RNA, as measured by
Polymerase Chain Reaction (PCR). This test must reach the laboratory within 6
hours of testing to be spun down and frozen (check with your local laboratory for
details).
• The mode of transmission has been shown to be primarily through intravenous
drug use, with needle or paraphernalia sharing. Sexual and vertical transmissions
are thought to account for less than 1% and 5% respectively. The infection rate
following a high-risk occupational exposure is estimated at 2%.
• Chronic HCV infection is often silent and is frequently discovered only at routine
serological testing. Overt clinical illness at sero-conversion occurs in less than
20% as evidenced by a mild viral illness, nausea, shivering or anorexia.  Jaundice
is reported in less than 10% of those acutely infected and fulminant hepatitis with
rash and arthropathy is unusual.
• 80% of patients do not clear the virus spontaneously. Patients who do clear the
virus do not have life long immunity against hepatitis C as there are many variant
strains and are they are therefore vulnerable to re infection.
• Patients whose HCV RNA is not detected may be retested annually if appropriate.
Patients whose HCV-RNA is detected should be referred for specialist review and
liver biopsy to determine the extent of liver damage if appropriate.  Treatment is
offered to those with chronic active disease (persistent viraemia). It is
recommended that it be offered to those patients stabilised on methadone
maintenance programmes and not using illicit drugs. Alcohol consumption is
contraindicated in HCV infected patients.
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• HCV infection is self-limiting in a percentage of infected individuals. The
prognosis in chronic infection varies greatly but it would appear that 30% of
patients ultimately develop cirrhosis within 30 years. Of those with cirrhosis,
hepatic carcinoma develops in approximately 6%. Factors affecting disease
progression include age at time of infection, alcohol abuse, co-existing HIV
and/or HBV infection.
• Currently treatment of HCV is with pegylated interferon and ribavirin. Pegylated
interferon is modified interferon polyethylene glycol (PEG) covalently bound to
interferon alpha with enhanced pharmacokinetic properties. The half-life of
interferon is extended. The pegylated interferon is administered subcutaneously
once a week and ribavirin is taken orally twice a day.  Treatment duration is
genotype dependant: 24 weeks for genotype 3 and 48 weeks for genotype 1. A
sustained viral response is documented by a viral clearance, an undetected HCV-
RNA six months after treatment completion.
• Response rates of up to 76-88% have been reported using combination pegylated
interferon alpha and ribavirin for 24 weeks with genotype 2/3 and 46-48% for 48
weeks with genotype 1.
• The most frequently reported side effects of treatment with interferon are ‘flu-
like’ symptoms.  Alopecia, insomnia, nausea, diarrhoea and psychiatric disorders
in particular depression and irritability are also commonly reported. Anaemia,
neutropenia, thrombocytopenia and altered thyroid function may also be
experienced.  The depression associated with interferon may lead to relapse in
drug use for some patients; hence appropriate selection is critical and close
psychiatric follow up is essential.
• Ribavirin treatment can result in a severe haemolytic anaemia. Ribavirin is also
teratogenic and all female treatment candidates must guarantee contraception, by
2 methods for the duration of treatment.  All male treatment candidates must
guarantee contraception with their female partners for the duration of the
treatment and for a follow up period of 7 months.
Summary: Hepatitis C
• Present in 62- 80% of drug users – including ‘heroin smokers’.
• 80% of patients who acquire hepatitis C don’t clear the virus spontaneously.
• PCR test identifies the 80% who have not cleared the virus.
• Patients who are not using illicit drugs and are PCR positive should be
referred to a Consultant Hepatologist.
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Remember:
• There are a number of Hepatitis C Liaison nurses appointed by the HSE
to link between the Hepatology departments in the major Dublin
Hospitals and the drug treatment services.
2 Human Immunodeficiency Virus
The human immunodeficiency virus (HIV) is an RNA virus.  Infection results in
progressive loss of immune function and to the development of the acquired immunity
deficiency syndrome, AIDS. Median time from infection to AIDS without treatment
is 10 to 14 years.
2.1 Immunopathogenesis
CD4 is a cell receptor for HIV, found on T-helper lymphocytes. The gp120/41
complex on HIV binds to CD4 to facilitate viral entry. Once inside the cell, viral RNA
is converted to DNA and is incorporated into the host genome. The virus uses the
cell’s ‘machinery’ to replicate and kills the cell in the process. The normal CD4 range
is 350-1500 cells/mm3. CD4 and viral load are surrogate markers of HIV disease. As
the disease progresses CD4 falls. The viral load is highest at extremes of infection,
seroconversion and late stage disease
2.2 The milestones in the history of HIV disease
• 1978-9 Recognition of AIDS
• 1983-4 Isolation of HIV – 1
• 1984 Advent of diagnostic testing
• 1987-88 Introduction of zidovudine
• 1996 Introduction of HAART (highly active antiretroviral therapy)
• 1996-7 Availability of viral load testing
2.3 Natural history of HIV disease
The HIV positive patient’s illness progresses through different stages. With treatment
however, this progression can be halted and even reversed. As the T-cell population is
depleted different signs/symptoms can be elicited.
• Up to 80% respond to treatment depending on genotype.
• Alcohol consumption has a critical influence on outcome and patients should
be advised to consume alcohol very moderately or to abstain entirely.
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2.4 Initial HIV infection
HIV is transmitted through certain body fluids and enters the body through mucous
membranes or direct contact with blood, semen, vaginal fluid, breast milk or other
body fluids containing blood.
2.5 Routes of HIV transmission
• Sharing needles.
• Unprotected vaginal/anal intercourse, increasing with concomitant STIs.
• Oral sex (less risky).
• Recipients of contaminated blood and blood products.
• Vertical transmission/breast feeding.
• Needle stick injuries.
Primary infection is usually asymptomatic but patients have mononucleosis like
illness (seroconversion illness)  2-6 weeks after exposure. At this stage the viral load
is high but declines.  The CD4 count drops then rises again but does not reach pre-
infection level. In early disease with a CD4 of >500 the majority are well but may
develop, seborrheic dermatitis, oral hairy leukoplakia or apthous ulceration.  There is
a slow progressive decline in CD4 – 48 to 80 cells/mm3/year/
In middle stage disease with a CD4 of 200-500 even with falling CD4, many at this
stage are well. Skin conditions predominate, seborrhoeic dermatitis, oral hairy
leukoplakia, apthous ulceration, recurrent Herpes simplex, varicella zoster and oral or
vaginal candidiasis.  Most clinicians would initiate treatment as the CD4 drops below
350.
In late stage disease with a CD4 of 50-200 patients may develop one of the AIDS
defining illnesses.  These illnesses include:
• Oesophageal candidiasis





• Lymphoma (EBV)/Kaposi’s sarcoma (HHV8)
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Prophylaxis against PCP is usually offered at this stage.  With advanced HIV disease
and a CD4 count of <50 death is likely within 2 years. Prophylaxis against
mycobacterium avium complex (MAC) is offered.
2.6 Treatment of HIV disease
HAART (highly active antiretroviral therapy/triple therapy) is a combination of
usually 3 or more antiretroviral medications. The medications include nucleoside
reverse transcriptase inhibitors, nucleotide reverse transcriptase inhibitors, non
nucleoside reverse transcriptase inhibitors, protease inhibitors and fusion inhibitors.
Reverse transcriptase inhibitors (NRTI) are nucleoside or nucleotide analogues
which compete with natural nucleoside or nucleotide substrate for binding to the
active site of reverse transcriptase.
• The nucleoside reverse transcriptase inhibitors include abacavir (ABA),
didanosine, lamivudine, stavudine, zalcitabine and zidovudine. The
nucleotide (phosphorylated nucleoside) analogues include tenofovir.
• Non nucleotide reverse transcriptase inhibitors (NNRTI) act by non
competitive inhibition of reverse transcriptase.  They include efavirenz,
neverapine and delavridine.
• Protease inhibitors (PI) bind to the active site of HIV protease enzyme and
prevent cleavage of polyproteins transcribed during HIV replication. Only non
infectious virus particles are produced.  The protease inhibitors include
ritonavir, saquinavir, nelfinavir, amprenavir atazanavir and indinavir.
• Fusion inhibitors inhibit membrane fusion between HIV and the T cell.
Enfuvirtide (Fuseon) is a fusion inhibitor administered sub cutaneously, twice
daily and is used as salvage therapy when all else has failed
2.7 When is HAART initiated?
Therapy is not routinely initiated at seroconversion except for the resolution of severe
symptoms. It is usually started with a CD4 count of <350, if the viral load is very high
or if the patient is symptomatic. Therapy is also recommended in pregnancy to reduce
vertical spread of the virus. It is used for post exposure prophylaxis, occupational or
non occupational.  Problems with HAART include side effects, resistant strains, poor
compliance, drug interactions, and methadone doses.
NRTI side effects include the class side effect of lactic acidosis, pancreatitis and
peripheral neuropathywith didanosine, zalcitabine and stavudine, lipodystrophy with
zidovudine and stavudine D4T, and a hypersensitivity reaction with abacavir.  The
NNRTI side effects  include vivid dreams or a  ‘feeling out of it’ with efavirenz and
rash/hepatitis (especially in pregnant women with T cell>250) with neverapine.  The
PI side effects include lipodystrophy/hyperlipidaemia/diabetes, nausea and vomiting,
hepatitis and nephrolitiasis with indinavir.
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Methadone is metabolised primarily by Cyp3A4 system. As all PPIs are CYP 3A4
inhibitors, the patient’s methadone level may increase and the daily methadone dose
may therefore need to be decreased. As Efavirenz, Ritonavir, Abacavir and
Neverapine all promote methadone metabolism by CYP3A4, the patient’s methadone
level may decrease and the daily methadone dose may therefore need to be increased.
2.8 Psychological aspects of HIV disease
Psychiatric disorders/substance misuse can be independent risk factors for HIV
infection. HIV is neuropathic and opportunistic infections or antretriviral drugs may
cause psychiatric symptoms. Psychiatric disease may affect adherence with
antiretroviral medications. Receiving a positive HIV diagnosis may cause
understandable feelings of loss, mood change, sexual/relationship issues, family
issues. More extreme responses could result in substance misuse, chronic distress/,
attempts at self harm or attempted suicide. It is important to watch for suicidal
ideation and to realise that the impact of diagnosis goes beyond the patient and may
involve loved ones, including partners, family members or care staff.
Psychological stress may be transitory and usually responds over a 6-12 month
period. In some cases may be more permanent and the prognosis is worse in those
suffering from social deprivation/isolation, poor coping skills, previous pre-morbid
psychiatric illness, personality disorder, previous sexual abuse or those in ethnically
marginalised groups.  Many drug users belong to one or more of the above groups.
2.9 Prevalence
Recent statistics from the Health Protection Surveillance Centre show that the
cumulative total of HIV cases reported to the end of December 2006 is 4,419.
2.10 HIV positive tests
• 30.0% intravenous drug users
• 21.9% homosexuals
• 18% heterosexuals/risk unknown
• 17% haemophiliacs/children and others
It is clear from these findings that intra-venous drug users (IVDUs) are at the high
risk of HIV infection and policies around drug treatment and harm minimisation must
take this into account.
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2.11 HIV Testing
Some at risk individuals self -refer for HIV testing. Others, particularly IVDUs should
have opportunistic screening.  There was a reluctance to test, in the past, because of
the limited treatment options and the poor outcomes of treatment. With the advances
in treatment modalities, this is no longer valid. The initial screening test is an Elisa
test. If positive this is followed by an immunoblot line assay (Western blot). The
advantages of testing include resolving uncertainty about HIV status, facilitating the
prevention of further transmission and to assist in informed decision making.
Disadvantages include psychological stress; a positive result may trigger depression
or suicide especially in the poor, IVDU or those with pre-existing psychiatric disease.
Some may need to defer testing until skills and supports are optimised.  There is also
an anxiety in keeping the result from friends and family and in negotiating sex.
There are certain issues, which should be discussed with a patient before a HIV test is
taken.
Pre-test discussion should include:
• The likelihood of a positive result
• Financial implications of testing and/or a positive result
• Identifying their support network
• What treatments are now available
• Confidentiality issues
• Results should be given by the person who organised the test
The timing of the test is important.  A HIV test is rarely urgent.  A period of three
months should elapse from the time of the risk behaviour and the testing time. This
will allow for an accurate result in 99% of cases. A baseline test may be warranted
following and occupational exposure or sexual assault or to allay anxiety.
Following the test result:
• If negative, reassure and advise about minimising future risk taking
behaviour.




The hepatitis B virus (HBV) is a double stranded DNA virus. Under electron
microscopy a number of particles are seen.  The whole virus is the Dane particle,
which consists of an inner core and an outer surface coat. The inner core contains
genetic material (DNA), DNA polymerase, an enzyme essential for reproduction, the
core antigen and the e antigen. The outer surface coat contains the surface antigen.
HBV infects more than 350 million people world-wide. It has an incubation period of
60-180 days. It is transmitted by the parenteral route, sexually and by blood to blood
contact. Intravenous drug users are at a high risk due to sharing needles or other parts
of the drug using paraphernalia. Of those infected, 95% usually recover fully, with
lifelong immunity against infection. In 2-5% the disease becomes chronic: fulminant
hepatitis occurs in 1%.
Chronic HBV infection is a serious liver disorder that may lead to the development of
hepatic failure, cirrhosis and hepatocellular carcinoma. It results in premature death in
15% to 25% of individuals infected. All patients found to have active infection should
be referred to a hepatologist for further evaluation.
3.1 Hepatitis B serological markers
There are three antigenic determinants (foreign antigenic particles) in the hepatitis B
virus:
HBsAg – Surface coat antigen. This antigen appears in the blood from about 6
weeks after an acute infection usually before jaundice is clinically evident.  It may
disappear or persist. Its presence indicates current infection or a chronic infection as
well as a carrier state. A carrier is defined as someone who is HBsAg positive on at
least two occasions, at least six months apart.
HBcAg – Core particle antigen. This antigen is not usually seen in the blood and
does not appear on the laboratory results.
HBeAg – e antigen.  This antigen is only detected in serum of patients in whom
HBsAg is also present. This rises early and declines rapidly. HBeAg is a measure of
viral replication.  It correlates with increased severity and infectivity and its
persistence correlates with the development of chronic liver disease or the Carrier
State.
Similarly, there are three antibodies which appear in response to the each of the above
antigens, Anti-HBs, Anti-HBc and Anti-HBe.
Anti-HBs - Anti surface antibody. This antibody is present in the serum of
convalescent patients, vaccinated subjects or carriers. It appears late and indicates
immunity.
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Anti-HBc – Anti core antibody.  The presence of this antibody suggests resolved
hepatitis B infection or low-level infection of minor clinical significance.  It may
persist for many years if not for a lifetime.
Anti-HBe – Anti e antibody. This antibody appears in the blood after the
disappearance of HBeAg and correlates with low infectivity.
If the anti-HBc (core antibody) is positive it means that the patient has had past
exposure to hepatitis B and may or may not have active infection at the time of
phlebotomy. If there is an antibody response to the core antigen there will be a similar
response to the surface antigen.  The Anti-HBs may be positive too. If the HBsAg
(surface antigen) is positive it indicates that the patient is actively infectious and the
infection may be acute or chronic. Remember a hepatitis B carrier (chronic infection)
is defined as someone who is HBsAg (surface antigen) positive on at least two
occasions, at least six months apart (2% to 5%). The patient has a 95% chance of
clearing the virus and in these cases the HBsAg (surface antigen) will be negative.
The anti-HBc (core antibody) will however remain positive indicating past infection.
Vaccination is not indicated in this case. If the anti-HBc (core antibody) IgM is
positive it will distinguish between acute and chronic hepatitis B infection.  A positive
anti-HBc IgM indicates acute infection.
In  the event of a positive HBsAg result  further serological tests, the HBeAg and the
anti-HBe should be performed.  These tests indicate the degree of infectivity or active
viral replication. A positive HBeAg and a negative Anti-HBe suggests active viral
replication, that the patient is highly infectious and the likelihood of viral clearance is
small. Similarly, a negative HBeAg and a positive Anti-HBe indicates that the active
infection will most likely clear and the patient may recover fully.
The hepatitis B vaccine differs from the natural hepatitis virus in that the host
(patient) is not injected with the complete hepatitis B virus but with the spherical
surface antigen.  Because it is free of genetic material which is in the core it is not
infectious and vaccination does not result in infection.  The body however reacts
against the foreign body hepatitis B surface antigen (HBsAg) by making antibodies to
this surface antigen so when natural exposure occurs i.e., the intact virus, the body
recognises the surface antigen component of the virus and already has antibodies to
hand to fight the infection immediately.
Anti-HBs on its own will only tell you the presence and the amount of Anti-HBs. It
will not differentiate between past natural exposure and vaccination. It is not a useful
test on it’s own for differentiating between past natural exposure and the need for
vaccination.  The Anti-HBc if positive will indicate past exposure: it could not be
positive following vaccination alone.
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4 Vaccination Schedules
Current recommendations18 suggest that all drug users, irrespective of their Hepatitis
C status, should be immunised against Hepatitis A and Hepatitis B (whether through
past exposure or by vaccination).
• If a patient is Hepatitis A antibody positive they will not require Hepatitis A
vaccine and in these cases Hepatitis B vaccine alone should be offered.
• If the patient is Hepatitis B positive, Hepatitis A vaccine alone should be
offered.
The combined HepA/HepB vaccine, the Hepatitis B vaccine and the Hepatitis A
should be available from the HSE to all GPs managing patients on the MTP.
The recommended schedule for either vaccine:
• At entry to treatment.
• At one month.
• At six months after the start of the program.
Post vaccination anti-HIB titres should be performed eight weeks after the last
vaccine.
Titre greater than 100 – patient is immune for life. A single booster against
Hepatitis A should be offered at ten years.
Titre (Miu/ml) between 10 than 100 – patient is termed a “poor responder” and
needs a booster of hepatitis B vaccine and a titre recheck at two months.
Titre (Miu/ml) less than 10 – patient deemed to be a “non-responder” and should
receive a full course of another brand vaccine, a double dose of a vaccine 9one
injection into each arm) or both.
We need to ensure that all patients are offered vaccination as soon as they enter
treatment.
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Chapter 11 Non-Methadone Alternative Therapies
While methadone treatment remains the mainstay of our treatment services there are
alternative substitute treatments available.
1 Buprenorphine (Subutex) and Buprenorphine/Naloxone
(Suboxone)
Buprenorphine and the Buprenorphine/Naloxone combination has a considerable
evidence base in its favour as a substitute treatment19. The evidence suggests that
buprenorphine is:
• As effective as methadone when given in equivalent doses
• Safer in overdose than methadone
In studies to date patients report feeling more alert and “clear headed” on
buprenorphine and it may suit patients who have a short addiction history. It may also
be useful in patients who have difficulty in detoxifying from a low methadone dose.
As with methadone either product should be administered under strict supervision
especially in the early stages of treatment. Caution needs to be exercised in patients
who are also abusing alcohol and benzodiazepines as there is a risk of overdose from
respiratory depression.
Currently buprenorphine is not available in primary care and is only available in a
limited way in treatment clinics
2 Lofexidine
Lofexidine does not have a full license in this country. It can be prescribed on a
named patient basis only. It is similar pharmacologically to Clonidine but does not
have the significant hypotensive effects. It has been found to be effective in patients
wishing to gain abstinence from heroin or from methadone and is useful in managing
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Dr. Ide Delargy, ICGP, 4-5 Lincoln Place, Dublin 2




Name:                                              Date:
You are now receiving a regular prescription for addictive medication and we ask
you to accept the following conditions and behave respectfully towards practice
staff.
1. I agree to attend appointments promptly and quietly.
2. I agreed to attend my appointments unaccompanied whenever possible.
3. I agree not to upset the Receptionist or other patients in the waiting room.
Behaviour outside these limits may result in the Receptionist or Doctors asking
you to leave the Surgery premises.
Prescription, Medication and Appointment:
1. I agree to be responsible for making my appointments and checking that
my appointment is correct in our appointment book.
2. I accept responsibility for turning up for my appointment on time.
3. I agree to attend on the Doctors mentioned below, on this form, and to
discuss my prescription with them.
4. I agree to use emergency appointments or house calls to discuss my
prescription.
5. I agree to be responsible for my prescription and medication and recognise
that these cannot be replaced.
6. I agree that no alteration will be made to my prescription without my own
Doctor’s permission.
My Doctor is Dr. _______________________ his/her half day is: _____________
In his/her absence I will consult Dr. ______________________________
I have read the above conditions, I understand what they mean and I agree to abide
by them.  If I do not abide by these rules then I understand that certain sanctions
may be imposed.  I understand that these sanctions are at the discretion of the
Doctor man may include:
1. Withdrawal of privilege e.g. take-away medication, supervision of
medication ingestion.
2. Transfer to another Doctor/Treatment Centre.
Signature: __________________________ (Patient)    Date: _________________




First Name:  ____________________
Last Name:  ____________________
Male             Female
D.O.B.







                                    Day   Month   Year
Age first took drugs:  ________________
First Drug:  ________________________
Age first took opiates:  _______________
First Opiate:  _______________________
Current Opiate:  _____________________
Route:  ____________________________
How Long:  ________________________
How Much:  ________________________
How often in the past Month
Daily Every 2nd Day
2-3 Days  Weekends Only
If not daily, are you getting withdrawals
                                                  Yes/ No
Are you currently injecting       Yes/ No
Ever Shared                                Yes/No






















Difficulty in controlling heroin intake
Has experienced withdrawal symptoms
Evidence of tolerance
Neglect of commitments
Persistent heroin misuse in spite of evidence of harmful effects
Currently in treatment Yes         No
Social History
Married Single      Separated/Divorced
Stable Relationship         Lone Parent
Living With:
Partner        Partner Taking Drugs
Parents       Parents Taking Drugs
Siblings      Siblings taking drugs
Living Alone       Living with children
Homeless
Living with other drug users
Family History of Alcohol   Yes/No
If Yes,  Mother         Father         Siblings
Mother Alive                        Yes/ No
If no, patient age at time of death          _______
Father Alive                          Yes/ No
If no, patient age at time of death         _______
Parents Together                   Yes/ No
If no, patient age at time of separation  _______
EDUCATION
Still at school                Yes/ No
Age left school              _______
Examinations Passed   ________
POST SCHOOL
Rehabilitation Course       Fas
Apprenticeship        CE Schemes
Third Level         Pre employment
Other
Employment Status




















Every in prison:               Yes/ No
On Probation:                  Yes/ No
Case Pending:                   Yes/No
Outstanding Warrant:      Yes/ No
HISTORY (PAST & PRESENT) OF PHYSICAL ILLNESS)
General Health Yes/ No  ________________________________________
Pregnant Yes/ No
DATE OF TEST
HIV status :             Never Tested                Positive               Negative
Hepatitis A status :  Never Tested               Positive               Negative
Hepatitis B status :  Never Tested               Positive               Negative




During the past 3 months you have felt:
Sad                           Yes/ No
Anxious                    Yes/ No
Frightened                 Yes/No
Guilty                        Yes/No
No Interest                Yes/No
Worthless                  Yes/No
Hopeless                                      Yes/No
Do you think life is worth living  Yes/ No
Do you think about suicide          Yes/No
If yes, have you planned to take your life
                                                      Yes/No
If yes, have you attempted to take your
life







Methadone Cocaine Amphetamines Tricyclic
PATIENTS GOALS & AIMS
Motivation on a scale of 1-5
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MANAGEMENT PLAN
Refer to Central Services                               Yes/No








All relevant information regarding urine sampling, transport of samples, cross
reactivity and excretion times are available through the Drug Analysis Laboratory: A
Guide to Service Users (Nov 2005): Drug Treatment Centre Board
Excretion Times

















Cocaine Metabolities 2-3 days
Methadone (maintenance dosing) 3 days
Codeine/Morphine/Propoxyphene
(Heroin is detected in urine as the
metabolite morphine)
48 Hours




3-8 days (up to 4 weeks)
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Appendix F
1. Daily Supervised Dispensing: Unstable Patient
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2. Three Times Weekly: Supervised Dispensing
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3. Stable Patient. Once Weekly Supervised Dispensing
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Once a Garda decides that he has sufficient evidence to prosecute (he may take advice
from the DPP) he formally reads the charge to the client.
Warrant:
If a person fails to turn up at court whilst on bail the judge issues a bench warrant,
which orders the Garda to arrest, and bring the person directly to court.
TR; Temporary Release:
An institution may release a person on license with instructions to present back to the
institution at a given time, usually weekly. Proof that the person is legally out of
prison is his TR form.
At large:
The person has failed to return to prison on time and can be arrested on sight and
returned to the institution.
Strung Out/or “sick”
Physically addicted but withdrawing




Needle Buzz, Smac, H


















Drug Dose Methadone equivalent
Street Heroin Cannot accurately be estimated because street drugs vary in
purity, though 1g of heroin are roughly equivalent to 50-80-

























Codeine linctus 100ml 300mg codeine phosphate 20mg






These conversions do not necessarily suffice for daily requirements because of the
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www.alcoholicsanonymous.ie  Self help group for alcohol dependence
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